SSRI联合低剂量阿司匹林与单药治疗的出血风险:系统综述与荟萃分析
该系统综述与荟萃分析检索多个数据库至2023年1月,纳入24项研究,评估SSRI联合低剂量ASA与单用SSRI或ASA相比的出血风险。主要结论为证据不确定性高,尚不支持SSRI加入低剂量ASA存在相互作用,但低剂量ASA加入SSRI可能增加出血风险,主要归因于ASA的启用。
要点
- SSRI联合低剂量ASA对比单用ASA,三项非随机研究的合并HR为1.37(95%CI 1.10-1.70)。
- SSRI联合低剂量ASA对比单用SSRI,一项RCT报告HR为1.82(95%CI 0.66-5.02)。
- 证据不确定性高,不能支持SSRI与低剂量ASA之间存在相互作用。
核心结论
- 汇总证据的不确定性过高,尚不能支持SSRI加入低剂量ASA时存在相互作用。
- 低剂量ASA加入SSRI可能意味着出血风险增加,主要归因于ASA的启用。
研究设计与样本
- 系统综述与荟萃分析,检索Medline、Embase、Cochrane Library、PsycINFO和Web of Science(从建库至2023年1月)。
- 共纳入24项符合PICO的研究,其中1项随机研究和6项非随机研究评估为无重大偏倚风险。
- 采用随机效应荟萃分析合并数据,并使用GRADE评估证据确定性。
主要发现
- SSRI联合ASA对比单用ASA:三项非随机研究(n=38 467)合并HR为1.37(95%CI 1.10-1.70;I2=0%)。
- SSRI联合ASA对比单用ASA:两项非随机研究(n=28 296)合并OR为0.95(95%CI 0.77-1.19;I2=0%)。
- SSRI联合ASA对比单用SSRI:一项RCT(n=1048)报告HR为1.82(95%CI 0.66-5.02)。
- 无SSRI治疗患者中ASA对比安慰剂:HR为1.60(95%CI 1.24-2.06)。
- SSRI联合ASA对比单用SSRI:一项非随机对照研究(n=18 920)报告IRR为1.03(95%CI 0.96-1.12)。
临床怎么用
- 临床决策时需认识到SSRI联合低剂量ASA的出血风险证据不确定性高,尤其应关注ASA启用带来的出血风险。
- 对于正在使用SSRI的患者,启用低剂量ASA前应评估出血风险,并加强监测。
局限性
- 纳入研究以非随机研究为主,仅一项RCT,且部分研究存在偏倚风险。
- 证据确定性按GRADE评估为不确定性高,限制结论的可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to systematically review whether concurrent treatment with an SSRI and low-dose ASA increases the risk of bleeding compared with treatment with an SSRI alone or ASA alone. METHODS: Medline, Embase, the Cochrane Library, PsycINFO and Web of Science (from database inception to January 2023) were searched according to PICO: P = patients on treatment with an SSRI and/or low-dose ASA; I = intervention: SSRI + ASA; C = comparison: ASA or SSRI alone; O = outcomes: bleeding/major bleeding. The included articles were assessed using checklists. Studies without major risk of bias formed the basis for the conclusions. Extracted data were pooled using random-effects meta-analyses. Certainty of evidence was assessed according to GRADE. RESULTS: Twenty-four studies met the PICO and were included. One randomized and six nonrandomized studies were assessed not to have major risk of bias. Regarding SSRI + ASA vs. ASA only, the pooled hazard ratio of three nonrandomized studies (n = 38 467) was 1.37 (95% confidence interval: 1.10; 1.70; I2 = 0%), and the pooled odds ratio of two nonrandomized studies (n = 28 296) was 0.95 (0.77; 1.19; I2 = 0%). Regarding SSRI + ASA vs. SSRI only, the randomized controlled trial (n = 1048) reported a hazard ratio of 1.82 (0.66; 5.02), the hazard ratio being 1.60 (1.24; 2.06) for ASA vs. placebo in patients without SSRI treatment; and one nonrandomized controlled study (n = 18 920) reported an incidence rate ratio of 1.03 (0.96; 1.12). CONCLUSIONS: The compiled evidence was too uncertain to support an interaction when an SSRI is added to low-dose ASA. Low-dose ASA added to an SSRI may imply an increased risk of bleeding primarily attributable to the initiation of ASA.
引用
- Axelsson MAB, Tukukino C, Parodi López N, et al. Bleeding in patients on concurrent treatment with a selective serotonin reuptake inhibitor (SSRI) and low-dose acetylsalicylic acid (ASA) compared with SSRI or low-dose ASA alone-A systematic review and meta-analysis. Br J Clin Pharmacol. 2024. PMID: 38351575. doi:10.1111/bcp.16000
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。